<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diffuse or multifocal ischaemic white matter lesions increase the risk of intracranial haemorrhage in patients using oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> for secondary prevention after <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> of arterial origin </plain></SENT>
<SENT sid="1" pm="."><plain>We studied whether neurologists could reliably assess the presence of these <z:hpo ids='HP_0002500'>white matter abnormalities</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>As part of the European/Australian <z:hpo ids='HP_0001297'>Stroke</z:hpo> Prevention in Reversible <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischaemia</z:e> Trial (ESPRIT), the severity of white matter lesions and presence of ischaemic lesions were twice assessed in a consensus meeting of three neurologists (from a pool of nine) as absent, moderate or severe, in a sample of 126 randomly selected CT or MRI scans </plain></SENT>
<SENT sid="3" pm="."><plain>The neurologists were not aware of the duplicate grading </plain></SENT>
<SENT sid="4" pm="."><plain>The degree of agreement between the first and second observation was calculated with kappa statistics </plain></SENT>
<SENT sid="5" pm="."><plain>The kappa value for agreement between the first and second assessment of white matter lesions was 0.58 (95% CI 0.40-0.76) </plain></SENT>
<SENT sid="6" pm="."><plain>The kappa value for the presence of clinically relevant and/or irrelevant ischaemic lesions was 0.68 (95% CI 0.58-0.78) </plain></SENT>
<SENT sid="7" pm="."><plain>Clinicians can assess the presence of white matter lesions with sufficient reliability </plain></SENT>
<SENT sid="8" pm="."><plain>Such assessment may prevent unnecessary risk with oral anticoagulation in secondary prevention after <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> of arterial origin, of which the efficacy is currently being assessed in ESPRIT </plain></SENT>
</text></document>